It is with great pleasure that the American Association for the Study of Liver Diseases (AASLD) and the Turkish Association for the Study of the Liver (TASL) announce our second joint conference to CONNECT physicians and health care providers in Turkey with experts from the USA and Turkey in hepatology.
AASLD is the global leader focused on advancing the science and practice of hepatology. Content delivered from our programs and journals, combined with local perspectives from experts in Turkey, have facilitated the incorporation of cutting edge research data into practice and offer the best possible atmosphere to encourage collaborative research between Turkish and American physicians.
This year, we have decided to take on the current challenges presented by the ongoing pandemic head-on and created a unique and exciting collaborative opportunity to link two meetings into a seamless, productive interactive experience. AASLD and TASL are working together to offer TASL attendees in our joint AASLD-TASL Digital Hepatology Connect to also register (at no additional cost) for The Liver Meeting Digital Experience™ 2020.
We truly believe that this arrangement for TASLD audience to participate in the two meetings will maximize learning about the latest liver disease research being presented at The Liver Meeting Digital Experience,™ followed, with the Hepatology Connect, by bringing the knowledge to life with more in-depth, case study-based discussions for state-of-the-art diagnosis and treatment approaches. The opportunity to interact with the unprecedented number of AASLD faculty and with local and regional experts in the science and practice of hepatology will make this a must-attend combination of events for the TASL audience.
We would be grateful to partner with organizations and companies that share our vision of collaboration and exchange. Support of this meeting is vital so that we can provide attendees with a quality meeting experience. Specifically, your support will help us deliver an exceptional scientific program via a digital platform that allows for large didactic lectures and smaller breakout sessions, as well as other opportunities for faculty and attendees to interact. Your participation will be mutually beneficial. There will be opportunities for satellite symposia and virtual exhibition space, and your involvement will provide exposure and brand recognition to extend your reach to hundreds of attendees.
On behalf of AASLD and TASL, we would like to thank you in advance for your financial contribution. Your support will play a crucial role in promoting liver health, providing quality patient care, and advancing the study and practice of hepatology in the region, especially in the area of viral hepatitis, chronic liver disease and hepatocellular carcinoma. It is because of supporters like you that we are able to plan and implement programs of this magnitude and collaboration on a global level. Your generosity directly allows us to carry out our mission to prevent and ultimately cure liver disease in Turkey, the US, and the world over.
Board Liaison, AASLD Global Outreach Committee
Co-organizer, AASLD-TASL Connect
Co-organizer, AASLD-TASL Connect
- Ramazan İdilman, M.D.
- W. Ray Kim, M.D
- Murat Akyıldız, M.D.
- Mehmet Demir, M.D.
|Before November 1, 2020||After November 1, 2020|
|Registration||3.000 TL||4.000 TL|
All registration fees excluding %18 VAT.
Registration fees includes the following services
- Participation to the scientific activites
Abstract submissions are now being accepted. Submit your work for consideration. Abstracts may only be submitted using the template on the conference’s abstract submission portal. For all accepted presentation, the presenting author is required to ensure that all co-authors are aware of the content of the abstract before submission. Please note that the abstract content may be edited at the discretion of the Scientific Committee.
Opens: Monday, October 5, 2020 at 9:00 am (Turkish Time)
Closes: Monday, January 3, 2021 at 22:00(Turkish Time)
Abstracts received after this deadline will not be accepted.
Abstracts submitted will be reviewed by the Scientific Committee for potential presentation. If selected, the presenting author will be required to accept the invitation to present, register for the conference, and provide current financial disclosure information. Abstracts may only be submitted using the template on the conference’s abstract submission portal. Abstracts submitted by fax or email will not be accepted. All abstracts must be submitted and presented in English. Please use US English spelling and have your abstract proofread for grammar and understanding. Please ensure that your abstract has never been presented before. If this rule is not respected, the abstract will be rejected and will not be considered for an AASLD – TASL Connect event.
Abstract notification will be sent to presenting authors by mid-February.
HEADER FOR ACCORDION – Abstract Submission Guidelines
The title should be brief, but long enough to identify the nature of the study. Omit author names and medical degrees and institutional appointments in the title. The maximum for the title character count is 300.
The body of the abstract needs to include:
- A background
- Description of methods
- Summary of results obtained
- Statement of conclusion reached
There is a set 3,000 maximum character count for the abstract body.
You may include any supporting images/tables. Images and tables are not a part of the overall character count.
Accepted files: pdf, jpg, jpeg, png, csv, doc(x), and ppt under 5MB
Only one presenting and corresponding author may be selected – see author definitions below
- Co-Author – One of several authors who provided a significant contribution to the abstract.
- Corresponding Author– This author will receive all notifications regarding the abstract, and will be expected to make any changes requested by the abstract reviewers.
- Presenting Author – The author who will be presenting the poster at the meeting.
The maximum number of authors on an abstract is 30.
For questions about the abstract submission process, please send an email to [email protected] . After having submitted your abstract, you will receive a confirmation by e-mail. Should you wish to make corrections to an abstract already submitted please contact the [email protected] Corrections to abstracts can only be made up to the announced submission deadline.
If an abstract is accepted, one author must attend the conference and present it in person. Acceptance of the abstract implies payment of the registration fee by the presenting author.
HEADER FOR ACCORDION – Abstract Policies
The initial responsibility for adherence to ethical guidelines lies with the responsible investigators submitting their research findings to AASLD - TASL Connect meeting. First, for reports of research using human subjects, provide assurance that (a) informed consent in writing was obtained from each patient and (b) the study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a prior approval by the appropriate institutional review committee. Refer to individual patients by number, not by initials. AASLD-TASL Connect meeting will only accept papers for review from liver transplant centers that explicitly state that no donor organs were obtained from executed prisoners or other institutionalized persons. Papers without such explicit statements will be returned without review.
Second, in studies involving animal experimentation, provide assurance that all animals received humane care according to the criteria outlined in the Guide for the Care and Use of Laboratory Animals [PDF] prepared by the National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985).
It is the policy of the AASLD and TASL to ensure balance, independence, objectivity, and scientific rigor in all its individually or jointly provided educational programs. All faculty/authors participating in any AASLD and TASL sponsored programs, as well as planners and committee members are expected to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing medical education program.
All abstract authors must complete their own financial disclosure statement either disclosing all financial relationships with commercial interests or indicating that none exist. Submitting authors will NOT be allowed to submit disclosures on a co-author's behalf.
Don’t accept less than VEMLIDY
Moderators: Selim Gürel, Ramazan İdilman
|Ray Kim, Robert S. Brown|
|18:30-18:40||Opening||Ramazan Idilman, Ray Kim|
| Viral Hepatitis
Moderators: Sabahattin Kaymakoğlu, Fehmi Tabak
|18:40-19:00||Briefing for the debrief||Norah Terrault|
|19:00-19:20||Debriefing the debrief||Paul Kwo|
|19:20-19:50||Case-based panel discussion
Case presenters: Kendal Yalçın, Suna Yapalı
|Norah Terrault*, Paul Kwo, Raymond Chung,
Ulus S. Akarca, Cihan Yurdaydın
Moderators: Abdullah Sonsuz, Yusuf Yılmaz
|20:20-20:40||Briefing for the debrief||Mary Rinella|
|20:40-21:00||Debriefing the debrief||Alina Allen|
|21:00-21:10||TASL NAFLD workshop summary||Dinç Dinçer|
|21:10-21:40||Case-based panel discussion
Case presenters: Yasemin Balaban, Gupse Adalı
|Alina Allen*, Mary Rinella, Mauricio Lisker-Melman, Fulya Günşar, Murat Kıyıcı|
|21:55-22:00||Day 1 Closing||Ray Kim|
| Trainee Workshop
Moderators: Saadettin Hülagü, Ramazan İdilman
|14:30-14:55||How to do database research||Elliot Tapper|
|14:55-15:20||How to do a meta-analysis||Fasiha Kanwal|
|15:20-15:40||How to read scientific papers||Raymond Chung|
|15:50-16:10||How to get my data published||Robert Brown|
|16:10-16:30||How to present my data||Jennifer Lai|
|16:30-17:30||Break out session
Moderators: Murat Akyıldız, Mehmet Demir
|Viral Hepatitis||Norah Terrault, Mauricio Lisker-Melman|
|Tenofovir Alafenamide in HBV: Real Life Data from Turkey||Fehmi Tabak|
|NAFLD||Alina Allen, Mary Rinella|
|Non-alcoholic fatty liver disease and extrahepatic malignancy||Mesut Gümüşsoy|
|HCC||Lewis Roberts, Paul Kwo|
|Etiologic, demographic and clinical characteristics of patients with hepatocellular carcinoma in Turkey: A multicenter study||Fatih Güzelbulut|
|Cirrhosis||Eliot Tapper, Jennifer Lai|
The Analysis of Liver Transplant Patients with COVID-19 Infection: A National Cohort
|Others||Robert Brown, Ray Kim|
|Evaluation of primary immunodeficiency in patients with autoimmune liver diseases||Şefika Nur Ayar|
Moderators: Nurdan Tözün, Orhan Sezgin
|17.30-17.50||TKI versus immunotherapy as first line therapy in HCC||Dilşa Mızrak Kaya versus Bülent Değertekin|
|17.50-18.10||Liver transplant for alcoholic hepatitis||Robert Brown versus Elliot Tapper|
Moderators: Hikmet Akkiz, Sedat Boyacıoğlu
|18.10-18.30||Briefing for the highlight||Denise M Harnois|
|18.30-18.50||TLMdX highlights: HCC||Lewis Roberts|
|18.50-19.20||Case-based panel discussion
Case presenter: Mesut Akarsu, Serkan Yaraş
|Denise Harnois*, Lewis Roberts, Ray Kim,
Meral Akdoğan, Yaman Tokat
Moderators: Zeki Karasu, Halil İbrahim Bahçecioğlu
|19.50-20.05||TLMdX highlights: cirrhosis||Jennifer Lai|
|20.05-20.20||TLMdX highlights: liver transplantation||Robert Brown|
|20.20-20.40||Debriefing the debrief||Mauricio Lisker-Melman|
|20.40-21.10||Case-based panel discussion
Case Presenter: Hale Gökcan, Cumali Efe
|Jennifer Lai*, Elliot Tapper, Robert Brown,
Halis Şimşek, Ahmet Gurakar
|21.25-21.30||Closing/evaluation||Ramazan Idilman, Ray Kim|
January 15,16 - 2021
Official Language of the meeting is English.
All abstracts must be sent by Abstract Submission System.
Registrants who require a letter of invitation will first need to complete the registration process for the congress.
Certificate of Attendance
Each participant will be given a Certificate of attendance on the last day of the congress.
Deadline for Early Registration: November 1, 2020
Deadline for Abstract Submission: January 3, 2021